5-Amino-1MQ

Rows are ordered by price per mg: listed price divided by stated peptide content, excluding shipping and codes, so every vial competes on the same axis. Each row carries its own $/mg figure, so the size of the gap between vendors is visible, not just the order. Sprays follow the vials, unranked.

The best-documented testing flag goes to the vendor publishing batch-level, third-party certificates. The shipping flag goes to the fastest published delivery from a domestic warehouse. Data is re-checked on a schedule and each row carries its verification date.

NNMT inhibitor studied for boosting NAD+, mitochondrial function, and metabolic health.

A small-molecule methylquinolinium inhibitor of nicotinamide N-methyltransferase (NNMT) characterised in the primary literature as a metabolic modulator in preclinical adipocyte and hepatocyte models. For laboratory characterisation only.

5-Amino-1MQ is a selective, membrane-permeable small-molecule NNMT inhibitor (EC50 ~2.3 µM in adipocytes) that blocks nicotinamide methylation to 1-MNA, preserving nicotinamide for NAD+ salvage, elevating NAD+ 1.2-1.6 fold, and activating Sirt1 for metabolic benefits including ~35% adipose reduction without appetite effects.

In-vitro enzyme assays report 5-amino-1MQ as a competitive inhibitor of NNMT with respect to the S-adenosylmethionine cofactor. NNMT inhibition is described in the literature as elevating cellular NAD+ pools.

In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

5-Amino-1MQ is a selective, membrane-permeable small-molecule NNMT inhibitor (EC50 ~2.3 µM in adipocytes) that blocks nicotinamide methylation to 1-MNA, preserving nicotinamide for NAD+ salvage, elevating NAD+ 1.2-1.6 fold, and activating Sirt1 for metabolic benefits including ~35% adipose reduction without appetite effects. It has a molecular formula C10H11N2O, mass 173.21 Da. Common synonyms in the literature include 5-Amino-1-Methylquinolinium, NNMT inhibitor, and 5A1MQ.

Investigation of 5-Amino-1MQ to date is primarily preclinical, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing 5-Amino-1MQ spans Adipocyte studies (in vitro): Differentiated adipocytes treated with 5-Amino-1MQ showed concentration-dependent NNMT inhibition with EC50 ~2.3 µM. Treatment reduced intracellular 1-MNA, elevated NAD+ 1.2-1.6 fold at 1-60 µM doses, increased SAM levels, and suppressed lipogenesis markers, Diet-induced obesity model (DIO mice): Systemic 5-Amino-1MQ treatment produced ~5.1% body weight loss (2.0 ± 0.6 g) and ~35% reduction in epididymal white adipose tissue (EWAT) mass. Adipocytes were smaller with reduced lipid content. Plasma cholesterol decreased. Critically, food intake was unchanged—effects were metabolic, not appetite-mediated, and Muscle and exercise studies: Aged mice treated with 5-Amino-1MQ showed improved running distance and reduced exercise recovery time, likely mediated by NAD+ elevation supporting mitochondrial function and Sirt1 activity in muscle tissue. Proposed mechanisms in the literature include Competitive NNMT inhibition: binds catalytic pocket, blocks nicotinamide → 1-MNA conversion (EC50 ~2.3 µM) and NAD+ salvage preservation: nicotinamide enters NAMPT → NMN → NAD+ pathway instead of methylation. None of this material describes therapeutic outcomes in humans, and No vendor listed here provides dosing guidance for 5-Amino-1MQ outside laboratory research.

For the full mechanistic profile, published references, and constraint notes on 5-Amino-1MQ, see the 5-Amino-1MQ research page. All references cited on that page are peer-reviewed primary literature.

Binding and functional-assay data for 5-Amino-1MQ, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.